Durvalumab: NICE recommends new lung cancer treatment
Intended for healthcare professionals
Clinical update Previous     Next

Durvalumab: NICE recommends new lung cancer treatment

Daniel Allen Health writer

Essential facts

A new lung cancer immunotherapy treatment should be made available to some lung cancer patients in England, according to the National Institute for Health and Care Excellence (NICE).

Cancer Nursing Practice. 18, 4, 11-11. doi: 10.7748/cnp.18.4.11.s11

Want to read more?

RCNi-Plus
Already have access? Log in

or

3-month trial offer for £5.25/month

Subscribe today and save 50% on your first three months
RCNi Plus users have full access to the following benefits:
  • Unlimited access to all 10 RCNi Journals
  • RCNi Learning featuring over 175 modules to easily earn CPD time
  • NMC-compliant RCNi Revalidation Portfolio to stay on track with your progress
  • Personalised newsletters tailored to your interests
  • A customisable dashboard with over 200 topics
Subscribe

Alternatively, you can purchase access to this article for the next seven days. Buy now


Are you a student? Our student subscription has content especially for you.
Find out more